MedTrace Logo

Full-Avoidance vs. Permissive/Regulated Drinking & Outcomes On Fibrillation

NCT06754176 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-12-23

No results posted yet for this study

Summary

The goal of this study is to assess the short-term effects of minimal and moderate drinking on atrial fibrillation (AFib) episodes in a real-world population diagnosed with 'come-and-go'/paroxysmal AFib. The question it aims to answer is:

Is there a greater occurrence of AFib episodes when participants are allowed to consume alcohol according to random assignment?

Participants will:

* Be given daily random assignments to avoid or not to avoid alcohol
* Wear an adhesive electrocardiographic (ECG) heart monitor
* Wear a wrist-worn fitness tracker
* Wear an anklet transdermal alcohol monitor
* Wear an adhesive glucose monitor
* Complete morning and evening surveys daily

Participants may be compensated up to $50 for full completion of the study. This study can be done in-person or remote.

Conditions

  • Atrial Fibrillation (AF)
  • Atrial Fibrillation (Paroxysmal)

Interventions

BEHAVIORAL

Alcohol Consumption Randomized Instructions

Alcohol Avoidance: In this intervention assignment, participants will be instructed to avoid drinking alcohol for this day. Alcohol Non-Avoidance: In this intervention assignment, participants will be allowed to drink alcohol for this day.

Sponsors & Collaborators

Principal Investigators

  • Gregory Marcus, MD, MAS · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-17
Primary Completion
2026-12-31
Completion
2029-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06754176 on ClinicalTrials.gov